Identification of compounds selectively killing multidrug-resistant cancer cells

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8293-8301

  Türk, Dóra ^a   Hall, Matthew D ^b   Chu, Benjamin F ^b   Ludwig, Joseph A ^d   Fales, Henry M ^c   Gottesman, Michael M ^b   Szakács, Gergely ^a  

^a INSTITUTE OF ENZYMOLOGY   (Hungary)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEREZONE; ANILINEPEREZONE; ANTINEOPLASTIC AGENT; ISOAMINOPEREZONE; NSC 10580; NSC 168468; NSC 292408; NSC 356777; NSC 403148; NSC 43320; NSC 641208; NSC 649816; NSC 651859; NSC 653864; NSC 672036; NSC 673999; NSC 681125; NSC 688942; NSC 693871; NSC 697120; NSC 697128; NSC 697135; NSC 697137; NSC 710857; NSC 713048; NSC 716765; NSC 716766; NSC 73306; NSC 86715; PEREZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CELL; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA MINING; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 70350537031     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2422     Document Type: Article

References (46)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234
2. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008;13:379-393
3. Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 2009;12:246-252
4. Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer 1999;81:423-430
5. Bentley J, Quinn DM, Pitman RS, Warr JR, Kellett GL. The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. Cancer Lett 1997;115:221-227 (Pubitemid 27196609)
6. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide- mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002;1:205-213
7. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6:129-137 (Pubitemid 39485685)
8. Warr JR, Quinn D, Elend M, Fenton JA. Gain and loss of hypersensitivity to resistance modifiers in multidrug resistant Chinese hamster ovary cells. Cancer Lett 1995; 98:115-120
9. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999;13: 768-778 (Pubitemid 29243629)
10. Lehne G, Sorensen DR, Tjonnfjord GE, et al. The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 2002;16:2388-2394 (Pubitemid 36054372)
11. Kaplan O, Jaroszewski JW, Clarke R, et al. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res 1991;51:1638-1644
12. Bell SE, Quinn DM, Kellett GL, Warr JR. 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer 1998;78:1464-1470 (Pubitemid 28517543)
13. Warr JR, Bamford A, Quinn DM. The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil. Cancer Lett 2002;175:39-44. (Pubitemid 33153042)
14. Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003;88: 1963-1970 (Pubitemid 36829675)
15. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-349 (Pubitemid 27051604)
16. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-766
17. Hall MD, Salam NK, Hellawell JL, et al. Synthesis, Activity, and pharmacophore development for isatin- β-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem 2009;52: 3191-3204
18. Ludwig JA, Szakacs G, Martin SE, et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006;66:4808-4815
19. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide. J Med Chem 1987;30:664-669
20. Wang H, Klinginsmith J, Dong X, et al. Chemical data mining of the NCI human tumor cell line database. J Chem Inf Model 2007;47:2063-2076 (Pubitemid 350275073)
21. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986;261:7762-7770 (Pubitemid 17208699)
22. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995;55:1086-1091
23. Wang E, Lee MD, Dunn KW. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug- resistant MES-SA/Dx5 uterine sarcoma cells. J Cell Physiol 2000;184:263-274 (Pubitemid 30432319)
24. Ujhelly O, Ozvegy C, Varady G, et al. Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum Gene Ther 2003;14:403-412 (Pubitemid 36308359)
25. Antholine W, Knight J, Whelan H, Petering DH. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol Pharmacol 1977;13:89-98. (Pubitemid 8027143)
26. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39:3-12. (Pubitemid 129682485)
27. Hall IH, Lackey CB, Kistler TD, et al. Cytotoxicity of copper and cobalt complexes of furfural semicarbazone and thiosemicarbazone derivatives in murine and human tumor cell lines. Pharmazie 2000;55: 937-941
28. Byrnes RW, Antholine WE, Petering DH. Interactions of 1,10-phenanthroline and its copper complex with Ehrlich cells. Free Radic Biol Med 1992;12:457-469
29. Shen AY, Wu SN, Chiu CT. Synthesis and cytotoxicity evaluation of some 8-hydroxyquinoline derivatives. J Pharm Pharmacol 1999;51:543-548 (Pubitemid 29319779)
30. Pierre JL, Baret P, Serratrice G. Hydroxyquinolines as iron chelators. Curr Med Chem 2003;10:1077-1084
31. Huang R, Wallqvist A, Covell DG. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem Pharmacol 2005;69:1009-1039 (Pubitemid 40349015)
32. Enriquez RG, Fernandez G. JM, Gnecco D, Penicaud A, Reynolds WF. The crystal and molecular structures of isoperezone, aminoperezone and isoaminoperezone: a comparative study of their crystal packing. J Chem Crystallogr 1998;28:529-537 (Pubitemid 128365359)
33. Cuellar A, Carabez A, Chavez E. Ca2+ releasing effect of perezone on adrenal cortex mitochondria. Life Sci 1987;41:2047-2054 (Pubitemid 18006134)
34. Kovacic P. Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications. Med Hypotheses 2007;69:510-516 (Pubitemid 47043281)
35. Huang Y, Blower PE, Yang C, et al. Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. Pharmacogenomics J 2005;5:112-125 (Pubitemid 40468118)
36. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-823
37. Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002;45:818-840
38. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 2006; 12:6876-6883 (Pubitemid 44974479)
39. Heffeter P, Jakupec MA, Korner W, et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 2007;73:1873-1886.
40. Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 1997;75: 810-815 (Pubitemid 27110695)
41. Blower PE, Yang C, Fligner MA, et al. Pharmacogenomic analysis: correlatingmolecular substructure classes with microarray gene expression data. Pharmacogenomics J 2002;2:259-271 (Pubitemid 35023584)
42. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103: 14901-14906 (Pubitemid 44527826)
43. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10.
44. Hall MD, Failes TW, Yamamoto N, Hambley TW. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans 2007:3983-3990 (Pubitemid 47384620)
45. Rappa G, Lorico A, Liu MC, et al. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 1997;54:649-655 (Pubitemid 27404624)
46. Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, Richardson DR. Iron chelators of the dipyr-idylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 2009;52:407-415